5 recruiting, 5 unknown, 3 completed, 2 terminated. 18 Phase 2, 6 Phase 3, 5 Phase 1.
Follow Malignancy: new trials by email Literature Review of Malignancy trials Research Report on Malignancy
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Off-Label Treatment With Immune Checkpoint Inhibitor Blockade One or more off-label ICIs alone or with other on-label ICI(s), Off-label ICI(s) with targeted therapy, off-label ICI(s) with other agents that are not targeted (including, but not limited to, chemotherapy, hormonal therapy, immunotherapy other than ICIs) with or without targeted agents - Malignancy | Phase 2 | Not yet recruiting | Medical College of Wisconsin | 231 | 2026-11-01 | 2026-08-10 |
| DETERMINE Trial Treatment Arm 03: Entrectinib in Adult, Paediatric and Teenage/Young Adult Patients With ROS1 Gene Fusion-Positive Cancers. Entrectinib - Haematological Malignancy, Malignancy | Phase 2 / Phase 3 | Recruiting | Cancer Research UK | 30 | 2025-11-30 | 2025-11-24 |
| Evaluating Informatics-assisted Immune-related Adverse Event Detection to Improve Registration Onto a Biorepository Informatics system for eligibility monitoring, Standard eligibility monitoring - Malignancy, Immune Related Adverse Events | Phase 1 / Phase 2 | Recruiting | Brigham and Women's Hospital | 100 | 2025-06-17 | 2025-06-19 |
| Immune Reconstitution Monitoring and Pneumococcal Vaccination in Patients Treated With CAR-T Cells Commercial CAR-T, Investigational CAR-T - Malignancy, Cancer | Phase 1 / Phase 2 | Withdrawn | UNC Lineberger Comprehensive Cancer Center | 2025-01-20 | 2026-01-06 | |
| DETERMINE Trial Treatment Arm 06: Capmatinib in Adult Patients With Cancers Harbouring MET Dysregulations Capmatinib - Solid Tumour, Haematological Malignancy | Phase 2 / Phase 3 | Recruiting | Cancer Research UK | 30 | 2024-11-19 | 2025-11-24 |
| DETERMINE Trial Treatment Arm 02: Atezolizumab in Adult, Paediatric and Teenage/Young Adult Patients With Cancers With High Tumour Mutational Burden (TMB) or Microsatellite Instability-high (MSI-high) or Proven Constitutional Mismatch Repair Deficiency (CMMRD) Disposition Atezolizumab - Malignancy, Malignant Neoplasm | Phase 2 / Phase 3 | Recruiting | Cancer Research UK | 30 | 2023-10-25 | 2025-11-24 |
| Application of Al18F-NOTA-FAPI PET/CT in Malignant Tumors Expressing Fibroblast-activated Proteins Al18F-NOTA-FAPI - Malignancy | Phase 2 / Phase 3 | Unknown | Cancer Institute and Hospital, Chinese Academy of Medical Sciences | 500 | 2023-01-08 | 2024-03-29 |
| Application of 18F-PSMA PET / CT Imaging in Prostate Specific Membrane Antigen Positive Tumor Al18F-PSMA-BCH PET/CT - Malignancy | Phase 2 | Recruiting | Cancer Institute and Hospital, Chinese Academy of Medical Sciences | 400 | 2022-10-13 | 2024-12-27 |
| Treatment of Malignant Tumors With NK Cell Decitabine combined with NK cell infusion - Malignancy | Phase 1 / Phase 2 | Unknown | Shenzhen University General Hospital | 60 | 2021-02-05 | 2021-12-03 |
| A Phase 1/2 Study of CYT-0851 in B-Cell Malignancies and Advanced Solid Tumors CYT-0851, CYT-0851 in combination with gemcitabine, CYT-0851 in combination with capecitabine - Malignancy, Non-hodgkin Lymphoma | Phase 1 / Phase 2 | Completed | Cyteir Therapeutics, Inc. | 169 | 2019-10-09 | 2024-12-24 |
| A Dose Escalation and Combination Immunotherapy Study to Evaluate BMS-986226 Alone or in Combination With Nivolumab or Ipilimumab in Patients With Advanced Solid Tumors BMS-986226, Nivolumab, Ipilimumab - Cancer, Tumors | Phase 1 / Phase 2 | Terminated | Bristol-Myers Squibb | 80 | 2017-09-01 | 2023-02-28 |
| Abatacept as GVHD Prophylaxis Phase 2 Abatacept, placebo - Graft vs Host Disease, Malignancy | Phase 2 | Completed | Boston Children's Hospital | 186 | 2013-02-01 | 2025-12-11 |
| Real-time Cancer Pain Assessment and Intervention real-time monitoring and instruction of cancer pain, standard cancer pain care - Malignancy, Pain | Phase 2 / Phase 3 | Unknown | Sun Yat-sen University | 200 | 2012-03-01 | 2015-08-27 |
| CO(Mbined Therapy of Malignant) S(Alivary Gland tu)M(Ours With)I(MRT and) c(Arbon Ions): COSMIC carbon ion boost - Malignancy, Salivary Glands | Phase 2 | Unknown | Heidelberg University | 54 | 2010-06-01 | 2013-04-24 |
| Pharmacokinetics of Thymoglobulin in Paediatric Haematopoietic Stem-cell Transplants Thymoglobulin (rATG) - Malignancy, Metabolic Disease | Phase 2 | Terminated | The Hospital for Sick Children | 30 | 2009-11-01 | 2019-11-04 |
| Virotherapy and Natural History Study of KHSV-Associated Multricentric Castleman s Disease With Correlates of Disease Activity Etoposide, Interferon-alpha, Rituximab - Lymphoproliferative Disorder, HHV-8 | Phase 2 | Active not recruiting | National Cancer Institute (NCI) | 75 | 2004-10-28 | 2026-10-23 |
| Allogeneic Transplantation From Related Haploidentical Donors non-myeloablative hematopoietic cell transplantation, Anti-Thymocyte Globulin, Cyclosporine - Blood Cancer, Leukemia | Phase 2 | Completed | Stanford University | 16 | 2000-08-01 | 2019-12-04 |
| Trial of Levofloxacin as Prophylaxis After Allogeneic Stem Cell Transplantation (SCT) Levofloxacin - Malignancy, Allogeneic Stem Cell Transplantation | Phase 2 / Phase 3 | Unknown | Charite University, Berlin, Germany | 2007-11-30 |
Neoplasms (18) · Hematologic Neoplasms (4) · Lymphoproliferative Disorders (3) · Neoplasms by Histologic Type (3) · Neoplasms by Site (3) · Glioma (2) · Graft vs Host Disease (2) · Leukemia (2) · Melanoma (2) · Multiple Myeloma (2) · Sarcoma (2) · Brain Neoplasms (1) · Breast Neoplasms (1) · Cancer Pain (1) · Colorectal Neoplasms (1)
Hemic and Lymphatic Diseases (7) · Immune System Diseases (7) · Immunoproliferative Disorders (6) · Lymphatic Diseases (6) · Hematologic Diseases (5) · Digestive System Diseases (3) · Digestive System Neoplasms (3) · Genital Diseases (3) · Lymphoproliferative Disorders (3) · Neoplasms by Histologic Type (3) · Neoplasms by Site (3) · Neoplasms, Germ Cell and Embryonal (3) · Neoplasms, Glandular and Epithelial (3) · Neoplasms, Nerve Tissue (3) · Neuroectodermal Tumors (3)
Antilymphocyte Serum (2) · Granulocyte Colony-Stimulating Factor (2) · Rituximab (2) · Abatacept (1) · Acetaminophen (1) · Bendamustine Hydrochloride (1) · Bortezomib (1) · Capecitabine (1) · Cyclophosphamide (1) · Cyclosporine (1) · Diphenhydramine (1) · Doxorubicin (1) · Drug Therapy (1) · Etoposide (1) · Filgrastim (1)
Cancer Research UK (3) · Cancer Institute and Hospital, Chinese Academy of Medical Sciences (2) · Boston Children's Hospital (1) · Brigham and Women's Hospital (1) · Bristol-Myers Squibb (1) · Charite University, Berlin, Germany (1) · Cyteir Therapeutics, Inc. (1) · Heidelberg University (1) · Medical College of Wisconsin (1) · National Cancer Institute (NCI) (1) · Shenzhen University General Hospital (1) · Stanford University (1) · Sun Yat-sen University (1) · The Hospital for Sick Children (1) · UNC Lineberger Comprehensive Cancer Center (1)
United States (8) · China (4) · Canada (3) · United Kingdom (3) · Germany (2) · Spain (1) · Switzerland (1)
Matthew Krebs, Dr (3) · Igor Wolfgang Blau, Dr. (1) · Leslie Kean, MD, PhD (1) · Li Yu, Dr (1) · Li Zhang, professor (1) · Marc W Muenter, MD (1) · Markus Renschler, MD (1) · Natalie Grover, MD (1) · Razelle Kurzrock, MD (1) · Robert Lowsky (1) · Robert Yarchoan, M.D. (1) · Rong Zheng, M.D. (1) · Rong Zheng, MD (1) · Tal Schechter-Finkelstein, MD (1)
PMID 20937120, PMID 21487108, PMID 22551422, PMID 24174627, PMID 25331113, PMID 33720337, PMID 37319437, PMID 38583802, PMID 38662981, PMID 38941593, PMID 41845569
2017 (1), R01CA294033 (1)